Subcutaneous dexmedetomidine for sedation of agitated delirium in palliative care

Article

LAPENSKIE, Julie | DOWNAR, James | WOLFE, Amanda | POLSKAIA, Nadia | VAN DEN BERG, Kate | WATT, Christine | BUSH, Shirley H. | BOESE, Kaitlyn | BARNES, Christopher J. | PARSONS, Henrique A. | KANJI, Salmaan | HEIDINGER, Brandon | LAWLOR, Peter G.

BACKGROUND: Agitated delirium frequently poses management challenges in palliative care. Interventions are needed to manage delirium yet allow meaningful end-of-life communication. Dexmedetomidine can provide wakeful sedation and may fill this therapeutic need. Our objectives were to study the safety and efficacy of using dexmedetomidine in inpatients with agitated delirium. METHODS: In a prospective study, ten adult patients received a dexmedetomidine infusion for agitated delirium in the Bruyère Health inpatient Palliative Care Unit. Following the introduction of an approved subcutaneous dexmedetomidine protocol, doses (range, 0.2-0.7 mcg/kg/h) were titrated to achieve wakeful sedation, targeting a Richmond Agitation-Sedation Scale Palliative version (RASS-PAL) level of -1 to +1. RESULTS: Seventy percent (7/10), 50% (4/8), and 83% (5/6) of patients achieved the RASS-PAL target sedation level at least once per day on Days 1, 2, and 3 of dexmedetomidine infusion, respectively. Those who did not consistently achieve target sedation typically died in less than 3 days. Most patients (n=7) received a maximum dexmedetomidine dose of 0.4-0.5 mcg/kg/h. Dexmedetomidine was discontinued prior to death in five cases due to perceived ineffectiveness (n=1), family requesting deeper sedation (n=1), asymptomatic hypotension (n=2), or bradycardia (n=1). In patients with transient hypotension or bradycardia, death occurred 19 h to 18 days following dexmedetomidine discontinuation. CONCLUSIONS: Subcutaneous dexmedetomidine infusion may be a safe and effective way of providing wakeful sedation for patients with agitated delirium in palliative care. However, prospective, controlled studies with standardized approaches to co-sedative and analgesia management are needed to better determine efficacy, adverse effects, and inform patient selection.

http://dx.doi.org/10.21037/apm-24-132

Voir la revue «Annals of palliative medicine, 14»

Autres numéros de la revue «Annals of palliative medicine»

Consulter en ligne

Suggestions

Du même auteur

Subcutaneous dexmedetomidine for sedation of ...

Article indépendant | LAPENSKIE, Julie | Annals of palliative medicine | n°1 | vol.14

BACKGROUND: Agitated delirium frequently poses management challenges in palliative care. Interventions are needed to manage delirium yet allow meaningful end-of-life communication. Dexmedetomidine can provide wakeful sedation and ...

Subcutaneous dexmedetomidine for sedation of ...

Article indépendant | LAPENSKIE, Julie | Annals of palliative medicine | n°1 | vol.14

BACKGROUND: Agitated delirium frequently poses management challenges in palliative care. Interventions are needed to manage delirium yet allow meaningful end-of-life communication. Dexmedetomidine can provide wakeful sedation and ...

Bereavement outcomes in family members of tho...

Article indépendant | DOWNAR, James | PALLIATIVE MEDICINE | n°6 | vol.36

Background: The COVID-19 pandemic has caused millions of deaths worldwide, leading to symptoms of grief among the bereaved. Neither the burden of severe grief nor its predictors are fully known within the context of the pandemic. ...

De la même série

Preparing for death : a survey on rituals in ...

Article | THIESBONENKAMP-MAAG, Julia | Annals of palliative medicine | n°1 | vol.14

BACKGROUND: In the majority of cultures, death is accompanied by a series of rituals that assist the bereaved in coping with this significant transition. However, there is a paucity of empirical literature on the organisation of s...

Palliative care in the older adult with advan...

Article | CHEN, Elaine | Annals of palliative medicine | n°1 | vol.14

Advanced lung disease, including chronic obstructive pulmonary disease (COPD) and various types of interstitial lung disease (ILD), are common disabling respiratory conditions with increasing prevalence in older adults. In this ch...

Subcutaneous dexmedetomidine for sedation of ...

Article | LAPENSKIE, Julie | Annals of palliative medicine | n°1 | vol.14

BACKGROUND: Agitated delirium frequently poses management challenges in palliative care. Interventions are needed to manage delirium yet allow meaningful end-of-life communication. Dexmedetomidine can provide wakeful sedation and ...

Caregiver needs in end-of-life care are diver...

Article | KOO, Alice | Annals of palliative medicine | n°2 | vol.14

BACKGROUND AND OBJECTIVE: Informal caregivers are essential to home-based end-of-life (EOL) care. However, their needs are often not well-understood and described in relation to caregiving, rather than with a 'caregiver-centric' p...

Discussing end-of-life care for persons exper...

Article | MOUREAU, Loïc | Annals of palliative medicine | n°2 | vol.14

BACKGROUND: End-of-life care for persons experiencing severe and persistent mental illness (SPMI) is a complex topic that deserves more attention. Despite growing awareness within international scientific research, topics such as ...

Chargement des enrichissements...